Found 5 matching trials
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC N/A This is an external control, observational, retrospective study designed to...
Show More Location
Memorial Sloan Kettering Cancer Center
Learn More & Join Trial
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC N/A This is a global, multicenter, open-label pre-approval access program to pr...
Show More Status
Approved For Marketing
Location
Multiple Locations
Learn More & Join Trial
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) PHASE3 This is an international, randomized, open-label, Phase 3 study designed to...
Show More Location
Hospital Britanico
Learn More & Join Trial
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors PHASE1 This is a Phase 1/2, open-label, first-in-human (FIH) study designed to eva...
Show More Location
Mayo Clinic Hospital
Learn More & Join Trial
A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC NA This study is a single-arm, multicenter real-world clinical study designed ...
Show More Location
Multiple Locations
Learn More & Join Trial